Multiple ascending dose study of BMS-582949 in patients with stable rheumatoid arthritis on the methotrexate background
Latest Information Update: 03 Nov 2021
At a glance
- Drugs BMS 582949 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 18 Dec 2007 Status changed from in progress to completed.
- 09 Oct 2007 Status changed from recruiting to in progress.
- 11 May 2007 study location added (Mexico)